Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.04.27.21256193: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This study was reviewed by the Mayo Clinic Institutional Review Board (IRB) and determined to be exempt from the requirement for IRB approval (45 CFR 46.104d, category 4). Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has several limitations. First, the study was conducted using data from a single …
SciScore for 10.1101/2021.04.27.21256193: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This study was reviewed by the Mayo Clinic Institutional Review Board (IRB) and determined to be exempt from the requirement for IRB approval (45 CFR 46.104d, category 4). Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has several limitations. First, the study was conducted using data from a single health system, with the vast majority of analyzed individuals residing in Minnesota or Wisconsin. The cohorts, which are over 90% Caucasian and approximately 54% female, are not demographically representative of the broader United States population that is now eligible for vaccination (Table 1). Second, the cohort analyzed is relatively small compared to the population analyzed in the phase 3 trial of Ad26.COV2.S and compared to our prior real world analyses of FDA-authorized mRNA vaccines 3,7. Finally, we did not assess the safety profile of Ad26.COV2.S here. It should be noted that we have previously performed a targeted investigation which showed that no individuals in the Mayo Clinic health system who received this vaccine have yet developed CVST, but this finding should also be taken in context of the very limited cohort size. Despite these caveats, this study is the first propensity matched real-world effectiveness assessment of Ad26.COV2.S. Implementation of this framework will allow us to track in real time how the effectiveness of this one-shot vaccine continues to evolve over the coming weeks. The extraction of such data from holistic health records inference is critical in shaping the global race against the ongoing pandemic. This information is particularly important in the context of variant emergence that could potentially escape vaccine-induced immunity. In addition, the...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
